Non-small cell lung cancer (NSCLC) is a form of lung cancer characterized by high incidence and low overall survival rates. The advent of immune checkpoint inhibitor therapy has transformed the treatment approach and clinical course of many cancers, including NSCLC. Monotherapy with immunotherapy or its combination with chemotherapy has become the established first-line treatment for advanced NSCLC without sensitizing mutations.

OBJECTIVE

To evaluate the efficacy of chemoimmunotargeted therapy (atezolizumab+paclitaxel+carboplatin+bevacizumab) in patients with advanced NSCLC in real-world clinical practice.

MATERIAL AND METHODS

The study included 25 patients aged 42 to 80 years who received chemoimmunotargeted therapy. Of these, 11 (44%) were treated in the first line, and 14 (56%) in the second or subsequent lines. An EGFR mutation was identified in 10 (40%) patients and an ALK translocation in 1 (4%).

RESULTS

The median follow-up was 11.7 (range 1.1—47.1) months. An objective response (complete+partial response) was achieved in 10 (40%) patients, while disease control (objective response+stable disease) was recorded in 23 (92%) patients. Median progression-free survival (PFS) and overall survival (OS) for first-line treatment were not reached. For second-line treatment, median PFS and OS were 8 months and 12.9 months, respectively. The safety profile was manageable, with 5 (20%) cases of immune-mediated adverse events reported.

CONCLUSION

The atezolizumab+paclitaxel+carboplatin+bevacizumab regimen represents a potential first-line treatment option for advanced NSCLC, including cases with EGFR mutations after progression on tyrosine kinase inhibitor therapy, regardless of PD-L1 status.